Gemcitabine and carboplatin induction chemotherapy followed by concurrent cisplatin and IMRT for locally advanced nasopharyngeal cancer

This study is testing a treatment approach for locally advanced nasopharyngeal cancer — a type of cancer that develops in the back of the nose and throat. The treatment combines two chemotherapy drugs (gemcitabine and carboplatin) given first to shrink the cancer, followed by radiation therapy with a precision technique called IMRT given at the same time as another chemotherapy drug (cisplatin). This combination approach aims to improve control of the cancer while limiting damage to surrounding tissues. You may be eligible if: - You have been diagnosed with WHO Type 2 or Type 3 nasopharyngeal cancer - Your cancer is at an advanced local stage (T3–T4) or has spread to nearby lymph nodes (N1 > 3 cm, N2–N3) - You have not had any prior cancer treatment - You have no prior chemotherapy or radiation therapy You may NOT be eligible if: - There are no additional exclusion criteria listed for this study Talk to your doctor about whether this trial might be right for you.